Loading
Serrated adenocarcinoma is a form of bowel cancer that grows out of sessile serrated polyps rather than ordinary adenomas, keeping their saw-tooth pattern. Most cases carry a KRAS or BRAF mutation and the BRAF-mutant ones are often mismatch-repair deficient. It is treated like other bowel cancer, with the BRAF and mismatch repair results guiding drugs when it has spread. Below, week by week, is what OnCo's record of Serrated adenocarcinoma of the colon and rectum says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Treated as the colorectal page by stage and molecular status: encorafenib with cetuximab for BRAF V600E metastatic disease, checkpoint inhibitors for MSI-high disease.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.